PRNewswire (Thu, 29-Jan 10:00 AM ET)
TipRanks (Tue, 27-Jan 8:30 AM ET)
Avista Healthcare Partners Announces Promotions
PRNewswire (Mon, 5-Jan 8:00 AM ET)
Organogenesis Announces Initiation of Biologics License Application for ReNu
Globe Newswire (Tue, 23-Dec 4:05 PM ET)
Globe Newswire (Mon, 15-Dec 4:25 PM ET)
ORGO Posts Record Q3 Revenue and Raises 2025 Guidance Amidst Strong Growth in Advanced Wound Care
Market Chameleon (Fri, 7-Nov 4:54 AM ET)
Organogenesis Reports Record Q3 Revenue and Boosts 2025 Guidance as Wound Care Drives Growth
Market Chameleon (Fri, 7-Nov 2:06 AM ET)
Globe Newswire (Thu, 6-Nov 4:05 PM ET)
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Organogenesis Holdings - Class A trades on the NASDAQ stock market under the symbol ORGO.
As of January 29, 2026, ORGO stock price climbed to $4.01 with 352,146 million shares trading.
ORGO has a beta of 1.59, meaning it tends to be more sensitive to market movements. ORGO has a correlation of 0.06 to the broad based SPY ETF.
ORGO has a market cap of $508.58 million. This is considered a Small Cap stock.
Last quarter Organogenesis Holdings - Class A reported $151 million in Revenue and $.18 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.11.
In the last 3 years, ORGO traded as high as $7.08 and as low as $1.80.
The top ETF exchange traded funds that ORGO belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
ORGO has underperformed the market in the last year with a return of +12.6%, while the SPY ETF gained +16.0%. In the last 3 month period, ORGO fell short of the market, returning -4.3%, while SPY returned +1.3%. However, in the most recent 2 weeks ORGO has outperformed the stock market by returning +3.6%, while SPY returned +0.5%.
ORGO support price is $3.74 and resistance is $4.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ORGO shares will trade within this expected range on the day.
